This study will evaluate the safety and tolerability of MK-8150 and its effect on central
systolic blood pressure (cSBP) and heart rate corrected augmentation index (AIx) when given
as single oral doses in healthy males and in males with mild-to-moderate hypertension. A
primary study hypothesis is that post dose mean change from baseline of time-weighted average
across 24 hours (TWA0-24hrs) cSBP or AIx is reduced in participants administered MK-8150
compared to placebo in males with mild to moderate hypertension. A mean decrease from
baseline compared to placebo of ≥5 mm Hg in TWA0-24hrs cSBP or of ≥5 percentage points in
TWA0-24hrs AIx is considered clinically meaningful.